The first synthetic CRISPR RNA arrayed library targeting nearly 8,000 genes provides a one-gene-per-well drug discovery screening tool for loss-of-function studies

Dharmacon™ Edit-R™ Human Druggable Genome crRNA Library from GE Healthcare’s Life Sciences business enables screening of nearly 8,000 individual targets with CRISPR-Cas9 gene knockout. The first arrayed synthetic CRISPR RNA (crRNA) library of its kind, it helps provide in-depth insight into a range of wide-reaching biological questions. With an emphasis on characterized genes of interest in drug discovery, it offers a powerful screening resource to identify potential therapeutic targets.

Arrayed screening lets researchers overcome the limitations of selectable or sortable assays that are required for pooled library screening. Edit-R Druggable crRNA Library delivers more detailed one-gene-per-well information by enabling high content and multiparametric assays to easily characterize complex phenotypes.

Ready-to-use, transfect